Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EB04
|
| gptkbp:CASNumber |
gptkb:162359-55-9
|
| gptkbp:hasInChIKey |
YQEZLKZALYSWHR-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C28H33N7O2
|
| gptkbp:hasSMILES |
CN1C=CC2=C1C=CC=N2
|
| gptkbp:hasUNII |
7A5I1C1L31
|
| https://www.w3.org/2000/01/rdf-schema#label |
162359-55-9
|
| gptkbp:IUPACName |
gptkb:N-(2-{2-Dimethylamino)ethyl}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
|
| gptkbp:mechanismOfAction |
gptkb:EGFR_tyrosine_kinase_inhibitor
|
| gptkbp:molecularWeight |
499.61 g/mol
|
| gptkbp:name |
gptkb:Osimertinib
|
| gptkbp:PubChem_CID |
gptkb:DB09330
CHEMBL3185146 71496458 |
| gptkbp:synonym |
gptkb:Tagrisso
gptkb:AZD9291 |
| gptkbp:usedFor |
treatment of non-small cell lung cancer
|
| gptkbp:bfsParent |
gptkb:Gilenya
|
| gptkbp:bfsLayer |
5
|